Sponsors

Lead Sponsor

Pfizer

This is a retrospective multicenter non-interventional study using real-world data collected from medical records of newly diagnosed AML or with relapsed/refractory B-cell ALL diagnosed between 01 January 2015 and 31 December 2019 in 4 Latin American countries: Argentina, Brazil, Chile, and Colombia. In addition, as secondary objectives, the study will also describe molecular profile, cytogenetic risk, clinical outcomes, and healthcare resource utilization of treated B-cell ALL R/R and AML patients.

Related studies

RECRUITINGPhase 1

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant

NCT06197672 · Acute Myeloid Leukemia

RECRUITINGPhase 1

Latin American Real-world Study in Acute Leukemia

What this study is about

Save this trial guide to your notes

Sponsors

Related studies

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant

Phase I Study of HC-7366 for Acute Myeloid Leukemia

Venetoclax Combined With Azacitidine for Consolidation Therapy in AML

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

Trial snapshot

Condition

Locations shown

For caregivers